Quince Therapeutics, Inc. (QNCX) Q1 2026 Annual Earnings
QNCX·Reported May 11, 2026·Before market open
Diluted EPS came in at $-0.59 (-73.5% YoY), beat the $-1.30 consensus by $0.71.
Diluted EPS
$-0.59beat by $0.71
Consensus: $-1.30
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Quince Therapeutics, Inc.'s Q1 2026 earnings report.
Quince Therapeutics, Inc. (QNCX) reported Q1 2026 earnings on May 11, 2026 before market open.
Quince Therapeutics, Inc. reported diluted EPS of $-0.59 for Q1 2026.
EPS beat the consensus estimate of $-1.30 by $0.71.
Compared to the same quarter a year prior, diluted EPS declined 73.5% from $-0.34.
You can read the 10-K periodic report (0001193125-26-151364) directly on SEC EDGAR. The filing index links above go to sec.gov.